[Federal Register Volume 59, Number 122 (Monday, June 27, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-15469]


[[Page Unknown]]

[Federal Register: June 27, 1994]


-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES
 

Opportunity For Licensing: Transforming Growth Factor--Beta

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Institutes of Health (NIH), Department of Health 
and Human Services (DHHS), seeks licensee(s) who can effectively pursue 
the preclinical, clinical and commercial development of transforming 
growth factor--beta (TGF-beta). In an earlier notice (Federal Register 
Vol. 58, No. 166 pages 45494-5, August 30, 1993) NIH had announced that 
several fields of use for TGF-beta were available for licensing. Since 
this time, two additional fields of use have become available for non-
exclusive licensing: 1) the nonsystemic administration of TGF-beta for 
repair of soft tissue; and 2) the systemic administration of TGF-beta 
for treatment or prevention of vascular ischemia and/or reperfusion 
injury. The following patents and patent applications covering TGF-beta 
are available to be licensed: U.S. Patent 5,104,977 entitled ``Purified 
Transforming Growth Factor Beta,'' U.S. patent application 08/048,956 
entitled ``Promotion of Cell Proliferation by Use of Transforming 
Growth Factor Beta,'' and foreign counterpart applications claiming 
priority from U.S. patent applications 06/468,590 and 06/500,833 both 
entitled ``Repair of Tissue in Animals.'' The patent rights in these 
inventions have been assigned to the United States of America.

SUPPLEMENTARY INFORMATION: The NIH seeks licensee(s), who in accordance 
with requirements and regulations governing the licensing of 
government-owned inventions (37 CFR part 404), have the most 
meritorious plan for the development of TGF-beta to a marketable status 
to meet the needs of the public and with the best terms for the NIH. 
The criteria that NIH will use to evaluate license applications will 
include, but not be limited to those set forth by 37 CFR 
404.7(a)(1)(ii)-(iv).

ADDRESSES: Requests for a copy of the patent applications, license 
application form, or other questions and comments concerning the 
licensing of this technology should be directed to: Mark D. Hankins, 
Technology Licensing Specialist, Office of Technology Transfer, 
National Institutes of Health, 6011 Executive Boulevard, Suite 325, 
Rockville, MD 20852-3804. Telephone: (301) 496-7735 ext. 265; 
Facsimile: (301) 402-0220. A signed confidentiality agreement will be 
required to receive copies of the patent applications.

    Dated: June 15, 1994.
Barbara M. McGarey, J.D.,
Deputy Director, Office of Technology Transfer.
[FR Doc. 94-15469 Filed 6-24-94; 8:45 am]
BILLING CODE 4140-01-P